HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $190 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Neurocrine Biosciences, maintaining a price target of $190.
August 29, 2024 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Neurocrine Biosciences, maintaining a price target of $190, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $190 price target by HC Wainwright & Co. suggests a positive outlook for Neurocrine Biosciences. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100